Summary
Health Canada has approved Lynkuet (elinzanetant), the first non-hormonal drug specifically authorized to treat moderate to severe hot flashes and night sweats in breast cancer patients on endocrine therapy. This landmark decision offers a targeted, non-hormonal alternative to off-label medications, helping patients manage treatment side effects without increasing cancer recurrence risks.
For women with breast cancer, hot flashes and night sweats aren’t just an inconvenience. They’re a side effect of the treatment keeping them alive, and until now, the options for managing them have been frustratingly limited.
That changed on August 17, 2026, when Health Canada authorized elinzanetant, sold under the brand name Lynkuet, specifically for breast cancer patients experiencing moderate to severe hot flashes and night sweats caused by endocrine therapy. It is non-hormonal, which matters enormously for this patient population.
Why This Gap Has Existed
About two-thirds of breast cancers are hormone-receptor positive, meaning they need estrogen to grow. Oncologists treat those cancers by blocking estrogen production, using medications like tamoxifen or aromatase inhibitors, often for five to ten years. The Canadian Cancer Society identifies tamoxifen and aromatase inhibitors as the most commonly used anti-estrogen medications in this context.
The problem is that suppressing estrogen triggers vasomotor symptoms: hot flashes and night sweats. And unlike other women experiencing menopause, breast cancer patients cannot take hormone replacement therapy to manage those symptoms, because hormones could stimulate cancer growth.
Until elinzanetant, oncologists were reaching for medications designed for other purposes entirely, including the anticonvulsant gabapentin and antidepressants like venlafaxine, trying to offer patients some relief through off-label use.
“We’ve been kind of pulling old drugs that would have a little bit of a benefit for our patients and decrease their hot flashes,” said Dr. Christine Brezden-Masley, medical director of the cancer program at Sinai Health in Toronto.
The stakes of getting symptom management right are high. Hot flashes and night sweats affect approximately 65% of women after breast cancer treatment, and nonadherence to endocrine therapy has been reported to range from 25% to 55%, with the development of adverse effects being the primary reason, according to research published in the Journal of Clinical Oncology. When patients stop taking their cancer medication to escape the symptoms, the risk of the cancer returning rises significantly.
What Elinzanetant Does
Elinzanetant works by targeting KNDy neurons, which can become hyperactive when estrogen drops and are responsible for triggering hot flashes and night sweats. By blocking neurokinin receptors on those neurons, the drug interrupts the process at its source, without involving hormones.
Health Canada first approved elinzanetant in July 2025 for hot flashes and night sweats in menopausal women generally. The expanded authorization for breast cancer patients was supported by the OASIS-4 trial, a Phase 3 randomized placebo-controlled study published in the New England Journal of Medicine.
The trial enrolled 395 women aged 18 to 70 who were receiving endocrine therapy for breast cancer and experiencing at least 35 moderate to severe hot flashes or night sweats per week. Over 52 weeks, those taking elinzanetant showed a significant reduction in daily hot flashes and night sweats, as well as fewer sleep disturbances, compared to those taking a placebo.
At the end of the trial, 91.6% of participants chose to continue taking elinzanetant for another two years. The most commonly reported side effects were daytime drowsiness, fatigue, and diarrhea.
What It Means for Patients
For Laurie Legere, a 47-year-old Toronto hospital administrator who was diagnosed with breast cancer at 44, the approval is personal. She has been managing hot flashes since chemotherapy put her into menopause, first during active treatment and now while taking endocrine therapy to prevent recurrence.
Sleep has been the hardest part. “You’re really trying to heal, you’re trying to rest, and it’s just kind of impossible,” she told Global News. She has already been prescribed elinzanetant and is looking forward to what she hopes will be a much better experience.
One Significant Caveat
A spokesperson for Bayer, the drug’s manufacturer, confirmed that elinzanetant is not currently publicly funded in Canada, and the price has not been disclosed. That means access will initially depend on private insurance or the ability to pay out of pocket, a real limitation for many patients.
The path to public coverage typically involves a review by Canada’s Drug Agency, the body that assesses whether drugs should be included in provincial formularies. That process can take months to years. Patients and oncologists will be watching that process closely.
Why This Is a Meaningful Step
This is not a cure, and it doesn’t change the underlying biology of breast cancer treatment. But for the many women who spend years on endocrine therapy struggling with debilitating symptoms, having a drug that was specifically studied and approved for their situation, rather than adapted from another context, represents a meaningful shift.
“The clinical trial with elinzanetant was the very first one that actually looked at breast cancer patients on anti-estrogen therapy,” Dr. Brezden-Masley noted. For a population that has historically been an afterthought in symptom management research, that’s significant.
For more information, visit Health Canada’s drug product database or speak with your oncologist or family doctor about whether elinzanetant may be appropriate for your situation.
Subscribe to The Health Insider newsletter where you’ll find many more insights – delivered straight to your inbox.
~ Read more from The Health Insider ~
- You’re Using Your Most Powerful Sense Wrong
SummarySmell is the only sense with a direct pathway to the brain’s emotional and memory centers. This guide breaks down the science behind smell-triggered memories, why olfactory loss can serve as an early warning sign for conditions like Parkinson’s, and how olfactory training can help protect cognitive health. Close your eyes and picture your grandmother’s… - A One-Time Gene Edit Could Lower Cholesterol for Life. Here’s Where the Science Actually Stands.New gene-editing trials show a single infusion can lower LDL cholesterol by over 50%. Learn how CRISPR tech could replace daily statins.
- The Science of Balance, Control, and Spatial Awareness: Why Proprioception MattersUnlock the secrets of proprioception. Learn why this hidden sense fails, how it changes with age, and simple ways to train your balance
- The Gut-Work Connection: Why Digestive Health is the Missing Piece in Workplace WellnessExplore why employee gut health is the next big workplace wellness trend and learn practical ways to boost your workday energy and comfort.
- You’ve Been Eating It For Years, And It Could Cause Harm To Your LiverIn Canada, high fructose corn syrup goes by glucose-fructose. Learn where this hidden sweetener lurks and how it impacts your liver health.
- Why Your Calf Muscle Is Considered Your Second HeartDiscover how your calf muscle acts as a second heart to boost circulation, prevent leg swelling, and support your vascular health.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
